Molecure Starts Share Sale, KRUK Buys €278 Million Italian Debt as Korab Flags 2020 Mining Objection
Molecure set out Tuesday to sell up to 4.12 million Series K shares, with two existing shareholders planning to offload as many as 2 million shares as part of the deal. The biotech, based in Warsaw, is seeking fresh capital with key clinical milestones on the horizon later this year. In Italy, KRUK signed on to buy as much as €278 million in unsecured retail receivables. Korab Resources, for its part, pointed investors again to its objection over a mining licence from December 2020. The wave of filings is notable: smaller listed names are still hustling—raising capital, deploying it, dealing with old legal baggage—instead of sitting on their hands waiting for markets to settle. Molecure’s latest fundraising comes as management insists its two leading programs are near key data points that could push investors to reassess the stock’s worth. Over at KRUK, Italy remains among the company’s significant markets.
